BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 21361739)

  • 1. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
    ; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
    Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
    Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccine acceptability among young adult men.
    Gerend MA; Barley J
    Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccines: an update for gynecologists.
    Ault KA
    Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
    Brotherton JM; Mullins RM
    Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age considerations when vaccinating against HPV.
    Wright TC; Huh WK; Monk BJ; Smith JS; Ault K; Herzog TJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S40-7. PubMed ID: 18482558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.